GOLD Criteria for Assessment of COPD and Treatment Options

GOLD Criteria for Assessment of COPD and Treatment Options 15 marks High-Yield Points The GOLD Initiative and Diagnosis

GOLD = Global Initiative for Chronic Obstructive Lung Disease, established 1997, first strategy report 2001, revised every November alongside World COPD Day.

Diagnostic criterion: in the right clinical context, a post-bronchodilator FEV1/FVC <0.70 confirms persistent airflow obstruction. Post-bronchodilator testing avoids labelling reversible disease (asthma) as COPD.

Geriatric caveat: the FEV1/FVC ratio falls physiologically with age, so the fixed 0.70 cut-off over-diagnoses COPD in normal older people. Pathy's and GOLD both prefer the lower limit of normal (LLN) in this age group. NICE adds that if FEV1 is ≥80% predicted, diagnose only when respiratory symptoms are present.

(a) Severity of airflow limitation (GOLD grades 1–4) — applied only once FEV1/FVC <0.7:

(b) Symptom burden — measured by the mMRC dyspnoea scale (cut-off ≥2) or the COPD Assessment Test, CAT (cut-off ≥10). CAT has 8 items scored 0–5, total 0–40.

(c) Exacerbation history in the past year — the strongest single predictor of future exacerbations. Group Definition — GOLD 2023–2025 Definition — GOLD 2026 (revised) A 0–1 moderate exacerbation, no hospitalisation; mMRC 0– No moderate or severe exacerbation; mMRC 0–1 or CAT 1 or CAT <10 <10 B 0–1 moderate exacerbation, no hospitalisation; mMRC No moderate or severe exacerbation; mMRC ≥2 or CAT ≥2 or CAT ≥10 ≥10 E ≥2 moderate exacerbations or ≥1 leading to ≥1 moderate or severe exacerbation in the past year, hospitalisation whatever the symptom score

Remember the history: the older ABCD tool used both symptoms and exacerbations for all four groups; GOLD 2023 merged C and D into a single group "E" (E for exacerbations) because exacerbation risk drives treatment more than symptoms do. GOLD 2026 has now lowered the entry threshold to Group E to a single moderate exacerbation.

Grading of exacerbation severity: mild — short-acting bronchodilators only; moderate — bronchodilators plus antibiotics and/or oral corticosteroids; severe — requires emergency department visit or hospitalisation. Treatment Options — Initial Pharmacological Therapy

Group A: a bronchodilator (short- or long-acting), chosen by symptom response. Group B: LABA + LAMA combination. Group E: LABA + LAMA; add ICS (triple therapy) if blood eosinophils ≥300 cells/µL.

Never use ICS alone in COPD. ICS are favoured when eosinophils are ≥300/µL, when there have been ≥2 exacerbations or a hospitalisation, or when asthma coexists; they are discouraged when there is repeated pneumonia, eosinophils <100/µL, or a history of mycobacterial infection — a point of particular importance in India, where past tuberculosis is common.

GOLD uses a review → assess → adjust cycle. Before escalating, always re-check inhaler technique, adherence, device suitability, non-pharmacological measures and comorbidities. GOLD 2026 clearly separates initial treatment (treatment-naive patient) from follow-up treatment (patient already on therapy).

If dyspnoea persists: escalate LABA or LAMA monotherapy to LABA+LAMA; if already on dual therapy, consider switching device or molecule and investigate other causes of breathlessness.

If exacerbations persist: escalate to LABA+LAMA+ICS when eosinophils are ≥100/µL. If exacerbations continue on triple therapy, add roflumilast (FEV1 <50% with chronic bronchitis), azithromycin (preferably ex-smokers; check QTc and hearing), or a biologic.

Core measures for every patient: smoking cessation, vaccination, pulmonary rehabilitation, physical activity, self-management education and written action plans, and post-exacerbation follow-up. GOLD 2026 elevates these to core disease-modifying strategies, not optional extras.

LTOT for chronic severe resting hypoxaemia; domiciliary NIV for persistent hypercapnia after hospitalisation for exacerbation; lung volume reduction surgery or endobronchial valves for selected upper-lobe emphysema; lung transplantation in very selected patients (rarely appropriate in the elderly).

Pulmonary rehabilitation in the elderly (Pathy's): patients are eligible from GOLD grade 2–4, but enrolment should be driven by symptoms and functional limitation, not FEV1 alone. It improves exercise tolerance, quality of life, dyspnoea, anxiety and depression, and reduces hospital days (10.4 vs 21 days in the year after rehabilitation) — but it does not improve survival, lung function or oxygen requirement. Benefits are not age-dependent, so age alone is never a barrier.